| payload |
{"created_at":"2026-04-10T03:04:31.796 {"created_at":"2026-04-10T03:04:31.796915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:8edb2e8d17a28469","evidence_event_ids":["evt_43efe7e7408d"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003301.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003301.txt","company":"Zeo ScientifiX, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003301.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_018928e613e6e69e","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003301.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:07:01.502448+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003301.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003301.txt","source_event_id":"evt_43efe7e7408d","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"49d4e09f7483e0f7","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-09","2026-04-10T03:04:31.796915+00:00"],"entities":[{"asset_class":"equity","name":"Zeo ScientifiX, Inc.","relevance":"high","symbol":"ZEOX","type":"issuer"},{"asset_class":"unknown","name":"Regen Therapy","relevance":"high","symbol":"","type":"counterparty"},{"asset_class":"unknown","name":"Stealth Health","relevance":"medium","symbol":"","type":"partner"},{"asset_class":"unknown","name":"Ian T. Bothwell","relevance":"medium","symbol":"","type":"signatory"},{"asset_class":"unknown","name":"Matthew Mazzuca","relevance":"low","symbol":"","type":"quoted_person"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; only that this 8-K was filed and what it contains.","The specific terms of the MOU (e.g., duration, exclusivity scope, financial terms, deliverables, regulatory status) are not included in the provided cleaned text beyond high-level positioning.","No explicit guidance or financial impact figures are stated in the provided text.","The filing\u2019s SEC Item number is provided (8.01), but no other material items are listed in the cleaned text beyond Exhibit 99.1."],"key_facts":["SEC filing: Form 8-K filed for Zeo ScientifiX, Inc.","Date of report / earliest event reported: April 9, 2026.","Item 8.01 Other Events: On April 9, 2026, ZEO issued a press release announcing an MOU with Regen Therapy for an exclusive scientific and biologics strategic collaboration.","The MOU is described as positioning ZEO as the core supplier of advanced biologic therapeutics to be incorporated into next-generation regenerative offerings on Regen\u2019s clinical platform.","A copy of the press release is included as Exhibit 99.1.","Exhibit 99.1 press release headline: \u201cRegen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics\u2014Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX (OTCQB: ZEOX)\u201d.","Press release states Regen Therapy has a network of more than 3,000 clinics and 24,000 practitioners across the U.S.","Press release states the collaboration creates a vertically integrated ecosystem combining clinical delivery, telemedicine infrastructure, and biologic product development.","Press release states participating clinics can integrate a licensed prescriber network, pharmacy fulfillment infrastructure, and telemedicine platform into existing operations.","Press release lists services mentioned as available to clinics/patients: physician-guided consultations, compounded medications, hormone replacement therapy, GLP-1 weight management programs, therapeutic peptides, and broader longevity protocols.","Press release includes a quote from Matthew Mazzuca, CEO and Co-Founder of Stealth Health."],"numeric_claims":[{"label":"clinics","value":"3,000"},{"label":"practitioners","value":"24,000"},{"label":"press release date","value":"2026-04-09"}],"primary_claim":"On April 9, 2026, ZEO issued a press release announcing it entered into an MOU with Regen Therapy for an exclusive scientific and biologics strategic collaboration positioning ZEO as the core supplier of advanced biologic therapeutics for Regen\u2019s next-generation regenerative offerings.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Zeo ScientifiX, Inc. (OTCQB: ZEOX) filed a Form 8-K on April 9, 2026 to report it entered into an MOU with Regen Therapy for an exclusive scientific and biologics strategic collaboration. The filing includes Exhibit 99.1, a press release describing ZEO as the core supplier of advanced biologic therapeutics for Regen\u2019s next-generation regenerative offerings.","topics":["SEC filing","Form 8-K","MOU","strategic collaboration","biologics","regenerative medicine","telemedicine","white-label platform","longevity programs","Exhibit 99.1"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Zeo ScientifiX, Inc. \u00b7 Filed 20260409","ticker":"ZEOX","tickers":["ZEOX"],"title":"ZEOX filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003301.txt"}}... |